Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries
Nov
2026
Description
This session covers advances in inherited metabolic liver diseases — Wilson disease, alpha-1 antitrypsin deficiency, and acute hepatic porphyria — including natural history data and emerging targeted therapies.
Presentations
11:00 AM
- 11:15 AM
Convention Center - Mile High Ballroom 2B-3B
Beyond Cirrhosis: Major Adverse Liver Outcomes Across PiMZ, PiSZ, and PiZZ Genotypes in Alpha-1 Antitrypsin Deficiency
Dustin Bastaich, PhD | Abstract Presenter
11:15 AM
- 11:30 AM
Convention Center - Mile High Ballroom 2B-3B
Atp7b inactivation disrupts hepatic metabolic zonation and drives diet-dependent steatohepatitis in a mouse model of Wilson Disease.
Mugagga Kalyesubula | Abstract Presenter
11:30 AM
- 11:45 AM
Convention Center - Mile High Ballroom 2B-3B
Defining the hepatic secretome in Wilson Disease using a lipid nanoparticle gene delivery system for proximity biotinylation of secreted proteins
Robert M Hughes, MD, PhD | Abstract Presenter
11:45 AM
- 12:00 PM
Convention Center - Mile High Ballroom 2B-3B
Real World Evidence of Therapy Impact in Unstable Wilson Disease using Non-Ceruloplasmin Bound Copper by Speciation as a Novel Monitoring Tool
Michael L. Schilsky, MD, FAASLD | Abstract Presenter
12:00 PM
- 12:15 PM
Convention Center - Mile High Ballroom 2B-3B
Analysis of Acute Hepatic Porphyria Metabolite (ALA/PBG) Fluctuations and Attack Rate With Givosiran Treatment in the Phase 3 ENVISION Study
Bruce Wang, MD | Abstract Presenter
12:15 PM
- 12:30 PM
Convention Center - Mile High Ballroom 2B-3B
Residual Hepatic, Neurologic, and Psychiatric Disease Burden in Treatment-Experienced Patients with Wilson Disease: Baseline Findings from the FoCus Phase 3 Trial
Frederick Askari, MD, PhD | Abstract Presenter
